Abstract YO3
Case summary
METASTATIC BREAST CANCER TO ESOPHAGUS: A CASE REPORT AND REVIEW OF THE LITERATURE
Secondary esophageal carcinoma from a breast primary is an infrequent phenomenon occurring in around 0.4% of patients. It is pertinent to rule out esophageal metastasis when a patient of breast carcinoma present with dysphagia after a long DFS. Most esophageal metastasis are usually submucosal deposition, requiring EUS-FNB for diagnosis. Given the rarity of this presentation and failure of diagnosis by simple mucosal biopsy during patient’s lifetime, there is a general lack of consensus on management guidelines in these patients.
Herein we report a case of 65 year old female presented with dysphagia who was subsequently diagnosed with esophageal metastases, 14years post surgery for breast cancer. She was treated with a combination of systemic Chemotherapy, hormonal therapy and local radiotherapy comprising both external beam radiotherapy(EBRT) and Intraluminal radiotherapy(ILRT). We also performed a comprehensive review of literature on esophageal metastases from breast primary, aiming to improve the diagnostic accuracy and treatment efficacy in this rare presentation. Our patient tolerated the treatment well and achieved a significant symptomatic improvement post Radiotherapy. Reviewing various literature, we observed 83% patients presented with complaints of dysphagia after a median of 13 years post breast surgery, with 72% metastases involving mid thoracic esophagus while majority were hormonally receptive.
We conclude that patients presenting with dysphagia post breast cancer treatment, should undergo EUS-FNB to rule out esophageal metastasis. While surgical interventions were effective treatment in some cases, we suggest systemic Chemotherapy with Hormonal therapy, and radiotherapy for local control as the management of choice in these patients. Even though prognosis is difficult to predict , this combined modality of treatment seems to achieve a better overall survival.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06